Axa S.A. Immunovant, Inc. Transaction History

Axa S.A.

$32.3 Billion
Q3 2024

A detailed history of Axa S.A. transactions in Immunovant, Inc. stock. As of the latest transaction made, Axa S.A. holds 98,838 shares of IMVT stock, worth $2.72 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

98,838

Previous 98,810 0.03%

Holding current value

$2.72 Million

Previous $2.61 Million 4.26%

% of portfolio

0.01%

Previous 0.01%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $770 - $770	28 Added 0.03%	98,838 $2.72 Million
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $1,405 - $1,770	56 Added 0.06%	98,810 $2.61 Million
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $847 - $1,226	28 Added 0.03%	98,754 $3.19 Million
Q4 2023 Jul 16, 2024	SELL	$31.31 - $44.19 $876 - $1,237	-28 Reduced 0.03%	98,726 $4.16 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $74,768 - $105,525	-2,388 Reduced 2.36%	98,726 $4.16 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $1.88 Million - $4.04 Million	101,114 New	101,114 $3.88 Million

Others Institutions Holding IMVT

# of Institutions

212

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account